國家衛生研究院 NHRI:Item 3990099045/16878
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2478239      線上人數 : 54
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/16878


    題名: Adverse effects of tyrosine kinase inhibitors on glucose and lipid metabolism in patients with chronic myeloid leukemia
    作者: Huang, RY;Tsai, HJ;Hsieh, KP;Chen, LT;Yang, YH
    貢獻者: National Institute of Cancer Research
    摘要: Background: The development of tyrosine kinase inhibitors (TKIs) significantly improved the prognosis of chronic myeloid leukemia (CML) patients. Adverse effects following long-term treatment are of concern; especially, cardiovascular events associated abnormal glucose-lipid metabolism. Objectives: This retrospective cohort study investigates the onset of high hemoglobin A1C (HbA1C), hypercholesterolemia, hypertriglyceridemia, and hyper-low density lipoprotein (LDL)-cholesterolemia in the patients treated with first-line TKI. Methods: CML patients aged over 20 years who had related laboratory data in the 6 months prior to the first-line TKI and within one year after TKI were selected. We extracted information from Taiwan National Health Insurance Database and laboratory data (2015–2020). Patients with other cancers history at baseline were excluded, and they were further grouped by the first-line TKI including imatinib, dasatinib and nilotinib. Time-to-event analysis and multivariable Cox regression was performed to analyze the probability of laboratory data over high cut-off values, including high HbA1C (≥ 6.5 %), hypercholesterolemia (≥ 240 mg/dL), hypertriglyceridemia (≥ 200 mg/dL), and hyper-LDL-cholesterolemia (≥ 160 mg/dL). Death, treatment discontinuation, switched to another TKI or the end of 1-year follow-up period were considered censored. Results: Nilotinib (N) users had higher risk than dasatinib (D) and imatinib (I) users in terms of hypercholesterolemia (N vs. I, hazard ratio, HR, [95% CI] = 3.90 [1.71–8.88]; N vs. D, HR = 2.60 [1.50–4.53]), hyper-LDL-cholesterolemia (N vs. I, HR = 2.91 [1.16–7.31]; N vs. D, HR = 2.15 [1.14–4.05]) and high HbA1C level (N vs. I, HR = 2.38 [1.50–3.78]; N vs. D, HR = 2.14 [1.39–3.28]). In patients without history of hyperlipidemia (N vs. I, HR = 7.61 [1.61–35.98]; N vs. D, HR = 4.33 [1.96–9.59]), without history of ischemic heart disease (N vs. I, HR = 4.36 [1.74–10.90]; N vs. D, HR = 2.76 [2.53–4.99]) or without diabetes (N vs. I, HR = 5.38 [1.87–15.47]; N vs. D, HR = 3.09 [1.67–5.71]), significantly higher risks of hypercholesterolemia were found in the nilotinib group. There was no significant difference for hypercholesterolemia onset in those with histories mentioned above. In patients with history of diabetes (N vs. I, HR = 2.3 [1.43–3.69]; N vs. D, HR = 2.18 [1.39–3.41]), significantly higher risks of high HbA1C level were found in the nilotinib group. No significant difference for high HbA1C level was found in those without diabetes history. Conclusions: Compared with imatinib and dasatinib, nilotinib is more likely to present adverse effects on blood glucose and lipids profile. Therefore, the selection of TKIs would need to consider patient's baseline comorbidity history.
    日期: 2024-11
    關聯: Pharmacoepidemiology and Drug Safety. 2024 Nov;33:165-166.
    Link to: http://dx.doi.org/10.1002/pds.5891
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1053-8569&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001407925901079
    顯示於類別:[楊奕馨] 會議論文/會議摘要
    [蔡慧珍] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI001407925901079.pdf78KbAdobe PDF13檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋